Orphina is a seed-stage biotechnology company focused on preserving and prolonging muscle health. Our initial clinical gene therapy program is for a rare disease with unmet medical need. Our technology is designed to allow re-dosing while limiting exposure to vital organs, with the aim of improving therapeutic effect and reducing the risk of severe side effects.